Thomas Kent - Tekla Healthcare Independent Trustee
| HQH Stock | USD 16.63 0.08 0.48% |
Executive
Mr. Thomas M. Kent CPA, is the Independent Trustee of the Company. Mr. Kent was a Partner at PricewaterhouseCoopers, LLP, where he served the Investment Management Industry for over 30 years, 24 years as a Partner. In so doing, he worked with and for more than 20 different and distinct Investment Company Boards, and along side several of those Boards service providers, including Advisors, Custodians, Accounting Agents, Transfer Agents, Security Pricing Providers, Tax advisors and others. His clients included both large and small fund groups, with both openend and closedend fund structures. Therefore, he provides the Funds with deep expertise in audit, valuation, operational and governance matters. He serves on both the Valuation Committee and the Audit Committee of each Fund. Mr. Kent also serves as a Director of Principal Global Investors Trust Co., a Trustee of Thayer Academy, and a Director of the New England Canada Business Council since 2017.
| Age | 67 |
| Tenure | 8 years |
| Professional Marks | CPA |
| Phone | 215 405 5700 |
| Web | https://www.teklacap.com/hqh.html |
Tekla Healthcare Management Efficiency
Tekla Healthcare's management efficiency ratios could be used to measure how well Tekla Healthcare manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Albert Laskaj | Cohen And Steers | 43 | |
| Mark Fetting | Eaton Vance Tax | 67 | |
| Helen Peters | Eaton Vance Tax | 73 | |
| George Gorman | Eaton Vance Tax | 69 | |
| Scott Whisten | Allianzgi Equity Convertible | 49 | |
| William Ogden | Allianzgi Equity Convertible | 75 | |
| Peter Hoglund | Royce Micro Cap | 54 | |
| Lisa Phelan | Cohen Steers Closed | 51 | |
| Rakesh Jain | Tekla Life Sciences | 69 | |
| Cynthia Frost | Eaton Vance Tax | 60 | |
| Thomas Faust | Eaton Vance Tax | 63 | |
| Laura Woodward | Tekla Healthcare Opportunities | 51 | |
| Laurie Lodolo | Flaherty and Crumrine | 56 | |
| Rakesh Jain | Tekla World Healthcare | 69 | |
| Linda Puchalski | Flaherty and Crumrine | 63 | |
| CFA CFA | Royce Micro Cap | N/A | |
| Lucinda Stebbins | Tekla Healthcare Opportunities | 73 | |
| Harriett Taggart | Eaton Vance Tax | 71 | |
| Richard Cochran | Allianzgi Equity Convertible | 59 | |
| Christopher Flynn | Royce Micro Cap | N/A | |
| Bradford Gallagher | Allianzgi Equity Convertible | 75 | |
Management Performance
| Return On Equity | 0.19 | |||
| Return On Asset | -1.0E-4 |
Tekla Healthcare Inv Leadership Team
Elected by the shareholders, the Tekla Healthcare's board of directors comprises two types of representatives: Tekla Healthcare inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Tekla. The board's role is to monitor Tekla Healthcare's management team and ensure that shareholders' interests are well served. Tekla Healthcare's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Tekla Healthcare's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christopher MBA, Senior Manager | ||
| Oleg Pohotsky, Independent Chairman of the Board of Trustees | ||
| Dr MS, Portfolio Manager | ||
| Lucinda Stebbins, Independent Trustee | ||
| Jeffrey Bailey, Independent Trustee | ||
| Daniel Omstead, CEO and President Trustee, Member of Valuation Committee, CEO of Hambrecht and Quist Capital Management LLC and President - HQL and President of Hambrecht and Quist Capital Management LLC and Trustee of HQL | ||
| Rakesh Jain, Independent Trustee | ||
| MBA MD, VP Mang | ||
| Frank Gentile, Senior Manager | ||
| Thomas Kent, Independent Trustee | ||
| William Reardon, Independent Trustee | ||
| Elizabeth Nabel, Independent Trustee | ||
| Laura Woodward, Chief Compliance Officer, Treasurer, Secretary |
Tekla Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Tekla Healthcare a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.19 | |||
| Return On Asset | -1.0E-4 | |||
| Profit Margin | 17.17 % | |||
| Operating Margin | (0.03) % | |||
| Current Valuation | 871.09 M | |||
| Shares Outstanding | 52.13 M | |||
| Shares Owned By Institutions | 23.89 % | |||
| Number Of Shares Shorted | 92.28 K | |||
| Price To Earning | 3.38 X | |||
| Price To Book | 0.83 X |
Currently Active Assets on Macroaxis
When determining whether Tekla Healthcare Inv offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Tekla Healthcare's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Tekla Healthcare Investors Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Tekla Healthcare Investors Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Tekla Healthcare Investors. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Stock space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tekla Healthcare. If investors know Tekla will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tekla Healthcare listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Tekla Healthcare Inv is measured differently than its book value, which is the value of Tekla that is recorded on the company's balance sheet. Investors also form their own opinion of Tekla Healthcare's value that differs from its market value or its book value, called intrinsic value, which is Tekla Healthcare's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tekla Healthcare's market value can be influenced by many factors that don't directly affect Tekla Healthcare's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tekla Healthcare's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tekla Healthcare is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tekla Healthcare's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.